2010
DOI: 10.1016/j.exer.2010.03.019
|View full text |Cite
|
Sign up to set email alerts
|

Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells

Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit COX activity, reduce the production of retinal VEGF and neovascularization in relevant models of ocular disease. We hypothesized that COX-2 mediates VEGF production in retinal Müller cells, one of its primary sources in retinal neovascular disease. The purpose of this study was to determine the role of COX-2 and its products in VEGF expression and secretion. These studies have more clearly defined the role of COX-2 and COX-2-derived prostanoids in r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
48
0

Year Published

2011
2011
2019
2019

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 47 publications
(48 citation statements)
references
References 54 publications
0
48
0
Order By: Relevance
“…33,34 In contrast, GFAP expression had a more modest increase at P18 in a2-null mice after hypoxia (Fig. 3A).…”
Section: Integrin-deletion Mitigates Müller Cell Activation and Vegf mentioning
confidence: 92%
See 3 more Smart Citations
“…33,34 In contrast, GFAP expression had a more modest increase at P18 in a2-null mice after hypoxia (Fig. 3A).…”
Section: Integrin-deletion Mitigates Müller Cell Activation and Vegf mentioning
confidence: 92%
“…4A). 23,30,33,34 Although a2-null retinas also developed a central avascular area due to capillary loss near the optic nerve, the avascular region was significantly diminished compared to the WT (Fig. 4A), indicating that a2b1 integrin-deletion protected from early vessel attenuation during hyperoxia.…”
Section: Integrin-deletion Protects Against Oxygeninduced Retinopathymentioning
confidence: 96%
See 2 more Smart Citations
“…Also, COX-2 may be a valuable molecular imaging biomarker for early detection of retinal diseases, staging of disease severity, and monitoring therapeutic response in patients with retinal disease including AMD and diabetic retinopathy. 12 …”
mentioning
confidence: 99%